The world's biggest CRO, Quintiles ($Q), had a good Easter as it was named the best CRO in Asia for the fourth time in 6 years.
The Durham, NC-based company won the accolade at the 2016 BioPharma Asia Industry Awards in Singapore. The award is given to the contract research organization that best shows an ongoing commitment to improving clinical research services in Asia and reducing lead times for customers.
"More than 1,000 votes were cast in the Best CRO category, and Quintiles was the overwhelming favorite," said Sharon Roessen, managing director of Terrapinn, organizer of BioPharma Asia Convention 2016.
"In addition to reducing lead times and advancing clinical research, Quintiles was chosen for its ability to deliver end-to-end solutions for customers and its outstanding thought leadership. Quintiles has clearly elevated clinical research standards in Asia-Pacific."
This comes after the CRO recently opened a new Greater China Regional Headquarters in Shanghai and became the first CRO in Japan to establish a regenerative medicine center of excellence (in the Kobe Biomedical Innovation Cluster).
Just last week it also got together with a number of Japanese and other international investors to create a new $866 million fund aimed at helping pharma companies--with previous funds being notably focused on those in Japan--with their drug development. Money will be paid back into the fund on successful completion of a trial.
- see the release